



**Montefiore** Montefiore Einstein  
Center for Transplantation

# *A Hepatitis C Primer for Non-Treaters*

---

***John F. Reinus, M.D.***  
***Medical Director of Liver Transplantation***  
***Montefiore-Einstein Center for Transplantation***  
***Professor of Clinical Medicine***  
***Albert Einstein College of Medicine***

# HCV infection: it's personal



## Achilles A. Demetriou, MD, PhD, Former Chair of Cedars-Sinai Department of Surgery, 1946-2013: Internationally Recognized Liver Surgical Scientist Dies After Fight with Liver Cancer

Article ID: 604889  
Released: 27-Jun-2013 3:00 PM EDT  
Source Newsroom: Cedars-Sinai

[Add to Favorites](#)

[more news from this source](#) [contact patient services](#)

[Facebook](#) [Twitter](#) [YouTube](#) [Google+](#) [SHARE](#)

**Newswise — LOS ANGELES —**  
June 27, 2013 — Achilles A. Demetriou, MD, PhD, an internationally distinguished surgical scientist who spent nearly four decades investigating and treating liver disease, and who led Cedars-Sinai's Department of Surgery to national distinction, has died. He was 67.



**MEDIA CONTACT**  
Available for logged-in reporters only

**CHANNELS**  
Recently Deceased

**KEYWORDS**  
Bioartificial Liver, Liver Disease, Demetriou, Liver Failure


# *Risk factors for HCV infection*

*Infection requires viral passage through protective anatomic barriers*

- Parenteral and intranasal drug use
- Transfusion of infected blood and blood products (before 1992)
- Other needle sticks: (amateur) tattoo; health-care workers (**surgeons**); dialysis
- Anal intercourse


# Prevalence of hepatitis C: NHANES

Denniston MM. Ann Intern Med. 2014;160:293-300



# Time course of disease progression

Hoofnagle JH. Hepatology. 2002;36:S21-S29.



# *Annual HCV disease progression*


Davis et al. Liver Transpl, 2003;9:331-338

Hornberger et al. J Viral Hepat, 2006;13:377-386

- Compensated cirrhosis, years 1-13: **0.6%**
- Compensated cirrhosis, year 14+: **2.3%**
- Decompensation: **4.0%**
- Cirrhosis to HCC: **4-8%**
- Transplantation: **4.3%**

# Estimated prevalence of cirrhosis

Davis et al. Liver Transpl, 2003;9:331-338



# AASLD & IDSA treatment guidelines

[www.hcvguidelines.org](http://www.hcvguidelines.org)

## *Recommendations for when and in whom to initiate treatment*

Treatment is recommended for **all** patients with chronic HCV infection, **except those with short life expectancies owing to comorbid conditions.**

**Rating:** Class I, Level A


Immediate treatment is assigned the highest priority for those patients with advanced fibrosis (Metavir stage F3), those with compensated cirrhosis (Metavir stage F4), liver transplant recipients, and patients with severe extrahepatic hepatitis C.

**Based on available resources, immediate treatment should be prioritized as necessary so that patients at high risk for liver-related complications are given high priority.**

**Ratings:** See tables



# Hepatitis C virus life cycle



# Generic-drug naming conventions


1. *Protease inhibitors*: names end with “PREvir,” e.g. simePREvir, paritaPREvir, grazoPREvir
2. *Polymerase inhibitors*: names end with “BUvir,” e.g. sofosBUvir, dasaBUvir
3. *NS5A inhibitors*: names end with “ASvir,” e.g. ledipASvir, velpatASvir, daclatASvir

# *FDA-approved all-oral treatment regimens for hepatitis C*

1. Epclusa™: *sofosbuvir/velpatasvir*
2. Harvoni™: *sofosbuvir/ledipasvir*
3. Mavyret™: *glecaprevir/pibrentasvir*
4. Technivie™: *paritaprevir/ombitasvir*
5. Viekira Pak™: *paritaprevir/dasabuvir/ombitasvir*
6. Vosevi™: *voxilaprevir/sofosbuvir/velpatasvir*
7. Zepatier™: *grazoprevir/elbasvir*

# Phase-3 trial: sofosbuvir/ledipasvir

Afdhal, et al. NEJM, 2014;370:1889



# *Factors affecting treatment choice*

- Insurance approval
- Viral genotype
- Renal function
- Presence of cirrhosis, decompensation
- Treatment history = resistance profile
- Potential drug-drug interactions

# AASLD & IDSA treatment guidelines


www.hcvguidelines.org



HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C



Home Test, Evaluate, Monitor Treatment-Naive Treatment-Experienced Unique Populations About



Search the Guidance

Enter your keyword:

Recent Announcements

21 Sep What's New, Updates, and Changes to the Guidance

This version of the guidance has been updated to reflect several important developments, including... [read more](#)

Start Here: Choose a patient profile from the menu above. ↑

### Welcome to HCVGuidelines.org

The AASLD and IDSA in partnership with the panel have created an updated web experience to facilitate easier and faster access to this important resource. Please select a patient profile from the menu above, click on a Guidance section below, or use the search box to begin.

- + Contents and Introduction - *Select a Page*
- + Testing, Evaluation, and Monitoring of Hepatitis C - *Browse Topics*
- + Initial Treatment of HCV Infection - *Choose Patient Genotype*
- + Retreatment of Persons in Whom Prior Therapy Has Failed - *Choose Patient Genotype*
- + Management of Unique Populations - *Review Recommendations*

# AASLD & IDSA treatment guidelines

www.hcvguidelines.org



HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C



Home | Test, Evaluate, Monitor | Treatment-Naive | Treatment-Experienced | Unique Populations | About

**Start Here:** Choose a patient profile from the menu above. ↑

## Welcome to HCVGuidelines.org

The AASLD and IDSA in partnership with the panel have created an updated web experience to facilitate easier and faster access to this important resource. Please select a patient profile from the menu above, click on a Guidance section below, or use the search box to begin.

**+** Contents and Introduction - *Select a Page*

**+** Testing, Evaluation, and Monitoring of Hepatitis C - *Browse Topics*

**-** Initial Treatment of HCV Infection - *Choose Patient Genotype*

- Initial Treatment of HCV Infection
- Treatment-Naive Genotype 1
- Treatment-Naive Genotype 2
- Treatment-Naive Genotype 3
- Treatment-Naive Genotype 4
- Treatment-Naive Genotype 5 or 6

**Search the Guidance**

Enter your keyword:

**Recent Announcements**

21 Sep What's New, Updates, and Changes to the Guidance

This version of the guidance has been updated to reflect several important developments, including... [read more](#)

# AASLD & IDSA treatment guidelines

www.hcvguidelines.org

Recommended and alternative regimens listed by evidence level and alphabetically for: Treatment-Naive Genotype 1a Patients Without Cirrhosis		
RECOMMENDED	DURATION	RATING <sup>1</sup>
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASs <sup>a</sup> for elbasvir	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup>	8 weeks	I, A
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	I, A
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for patients who are non-black, HIV-uninfected, and whose HCV RNA level is <6 million IU/mL	8 weeks	I, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A
ALTERNATIVE	DURATION	RATING <sup>1</sup>
Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) as part of an extended-release regimen or plus twice-daily dosed dasabuvir (250 mg), with weight-based ribavirin	12 weeks	I, A
Daily simeprevir (150 mg) plus sofosbuvir (400 mg)	12 weeks	I, A
Daily daclatasvir (60 mg) <sup>c</sup> plus sofosbuvir (400 mg)	12 weeks	I, B
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) with weight-based ribavirin for patients with baseline NS5A RASs <sup>a</sup> for elbasvir	16 weeks	IIa, B

<sup>a</sup> Includes genotype 1a resistance-associated substitutions at amino acid positions 28, 30, 31, or 93 known to confer antiviral resistance.

<sup>b</sup> This is a 3-tablet coformulation. Please refer to the prescribing information.

<sup>c</sup> The dose of daclatasvir may need to increase or decrease when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. Please refer to the prescribing information and the section on HIV/HCV coinfection for patients on antiretroviral therapy.



# Drug-drug interactions:

Bioavailability of drugs is dependent on factors that alter their metabolism and intracellular concentration through:

- *Induction or inhibition* of CYP3A4 (metabolizes > 50% of FDA-approved drugs including many DAAs)
- *Induction or inhibition* of membrane transporters [OATP, BCRP (ABCG2), P-gp (ABCB1, MDR1)] responsible for cellular uptake and elimination of organic compounds

**This is a mutual effect of drugs on each other: victims and perpetrators**

# Drug-drug interactions: Viekira Pak™ (steps 1-3)

Component	Role	Enzymes	Transporters
Paritaprevir (ritonavir-boosted)	Victim	Substrate of CYP3A4	Substrate of P-gp, BCRP and OATP1B1
	Perpetrator	Inhibits multiple enzymes	Inhibits P-gp, BCRP and OATP1B1/3
Ombitasvir	Victim	Substrate of CYP3A4	Substrate of P-gp
	Perpetrator	Inhibits multiple enzymes	
Dasabuvir	Victim	Substrate of CYP3A4 and others	Substrate of P-gp
	Perpetrator	Inhibits UGT1A1	Inhibits BCRP

# Hepatitis C drug interactions

www.hep-druginteractions.org

The screenshot shows the top navigation bar of the HEP Drug Interactions website. On the left is the logo for HEP Drug Interactions. In the center is the University of Liverpool logo. On the right are two buttons: 'Donate Now' and 'Interaction Checker', both with right-pointing arrows. Below the logo area is a horizontal menu with the following items: 'Interaction Charts', 'Site Updates', 'Interaction Query Service', 'About Us', 'Pharmacology Resources', 'Contact Us', and 'Support Us'. At the bottom of this section is a green banner with the text: 'HEP iChart app users - please update to the newest version to ensure up-to-date information'.

## HEP Drug Interaction Checker

Access our comprehensive, user-friendly, free drug interaction charts. Providing clinically useful, reliable, up-to date, evidence-based information

Start Now →

The screenshot shows the main interface of the HEP Drug Interaction Checker. It features a legend at the top with four categories: 'Do Not Coadminister' (red circle), 'Potential Interaction' (orange square), 'No Interaction Expected' (green diamond), and 'No Clear Data' (grey diamond). Below the legend is a table with columns for various HCV drugs and rows for various interacting drugs.

	Daclatasvir	Elbasvir/Grazoprevir	Ledipasvir/Sofosbuvir	OBV/PTV/r + DSV	Simeprevir	Sofosbuvir
Amiodarone	●	■	●	●	■	●
Antacids	◆	◆	■	◆	◆	■
Aspirin	◆	◆	◆	◆	◆	◆
Cannabis	◆	◆	◆	■	■	◆
Carbamazepine	●	●	●	●	●	●
Ciclosporin	◆	●	■	■	●	◆
Dabigatran	■	■	■	■	■	◆

# *Hepatitis C therapy: conclusions*

- Simple
- Well tolerated
- Multiple options
- Highly effective

**Diagnose and treat patients before they develop end-stage liver disease and liver cancer**